Afsane Bahrami, Thozhukat Sathyapalan and Amirhossein Sahebkar* Pages 1757 - 1774 ( 18 )
Atherosclerosis (AS), as a chronic inflammatory disorder of the cardiovascular system, is one of the leading causes of ischemic heart disease, stroke and peripheral vascular disease. There is growing evidence on the role of innate and adaptive immunity in the pathogenesis of atherosclerosis. Interleukin-18 is one of the novel proinflammatory cytokines involved in atherogenesis, atherosclerotic plaque instability and plaque rupture. In this review, we overview the findings of preclinical and clinical studies about the role and mechanism of action of IL-18 in the pathogenesis of AS, which could offer novel prognostic and therapeutic approaches.
Matrix metalloproteases, acute coronary syndromes, vascular smooth muscle cells, polymorphism, atherosclerosis, Interlukin-18, therapeutic.
Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, Halal Research Center of IRI, FDA, Tehran